Dermapharm Holding SE (DMPHF)
OTHER OTC:DMPHF
DMPHF Stock Chart & Stats
$54.14
--
Market closed
$54.14
--
Day’s Range― - ―
52-Week Range$34.96 - $59.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$2.65B
Enterprise Value$3.23B
Total Cash (Recent Filing)$225.93M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)17.3
Beta0.46
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.42%
Share Statistics
EPS (TTM)2.69
Shares Outstanding49,540,810
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda9.70
Forecast
1Y Price Target
$60.01Price Target Upside10.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.98
Revenue Forecast (FY)$1.40B
Bulls Say, Bears Say
Bulls Say
Vertically Integrated Business ModelDermapharm's integrated model—R&D, in‑licensing, commercial brands plus contract manufacturing and OTC—creates multiple durable revenue channels. Vertical integration supports margin capture, capacity leverage and cross‑selling, reducing reliance on a single product or channel.
Strong Free Cash Flow GenerationSustained, sizable free cash flow provides durable financial flexibility for reinvestment, bolt‑on deals, deleveraging or shareholder returns. High FCF conversion versus net income indicates earnings translate into cash, supporting strategic optionality over the medium term.
Healthy Profitability And ROEAbove‑average EBIT and net margins alongside strong return on equity signal competitive product economics and efficient capital use. These durable profitability metrics support internal funding for growth and suggest the business can generate attractive returns on incremental investment.
Bears Say
Elevated LeverageDebt remains meaningfully elevated despite improvement, increasing interest and refinancing risk. High leverage constrains strategic flexibility, limits capacity for large acquisitions or capex without further funding, and heightens vulnerability to cyclical or regulatory shocks.
Margin VolatilityMaterial swings in margins over recent years reduce predictability of earnings and cash flow. Volatility likely stems from product mix, pricing/reimbursement and cost dynamics, complicating budgeting and making long‑term margin sustainability less certain for investors and management planning.
Sub‑par Operating Cash ConversionOCF trailing net income at ~0.62x points to working‑capital timing or collection issues that can produce cash variability. Persistent conversion gaps can impede debt paydown, opportunistic investments or dividend stability even when accounting earnings appear solid.
Dermapharm Holding SE News
DMPHF FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
Dermapharm Holding SE lowest stock price was $34.96 and its highest was $59.55 in the past 12 months.
What is Dermapharm Holding SE’s market cap?
Dermapharm Holding SE’s market cap is $2.65B.
When is Dermapharm Holding SE’s upcoming earnings report date?
Dermapharm Holding SE’s upcoming earnings report date is Aug 25, 2026 which is in 76 days.
How were Dermapharm Holding SE’s earnings last quarter?
Dermapharm Holding SE released its earnings results on May 13, 2026. The company reported $0.978 earnings per share for the quarter, beating the consensus estimate of N/A by $0.978.
Is Dermapharm Holding SE overvalued?
According to Wall Street analysts Dermapharm Holding SE’s price is currently Undervalued.
Does Dermapharm Holding SE pay dividends?
Dermapharm Holding SE pays a Annually dividend of $0.747 which represents an annual dividend yield of 2.42%. See more information on Dermapharm Holding SE dividends here
What is Dermapharm Holding SE’s EPS estimate?
Dermapharm Holding SE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermapharm Holding SE have?
Dermapharm Holding SE has 49,540,810 shares outstanding.
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Dermapharm Holding SE reported an EPS of $0.978 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.689%.
Which hedge fund is a major shareholder of Dermapharm Holding SE?
Currently, no hedge funds are holding shares in DMPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dermapharm Holding SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$60.01 (10.84% Upside)
$60.01 (10.84% Upside)
Insider Transactions
Bought Shares
Worth $20.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.31%
12-Months-Change
Fundamentals
Return on Equity
21.44%
Trailing 12-Months
Asset Growth
7.62%
Trailing 12-Months
Company Description
Dermapharm Holding SE
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
DMPHF Stock 12 Month Forecast
Average Price Target
$60.01
▲(10.84% Upside)
Ownership Overview
89.83% Insiders
2.72% Mutual Funds
― Other Institutional Investors
6.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---